NCT06528847View on ClinicalTrials.gov

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2030

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Benmelstobart

The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER